La liraglutida es un agonista del receptor de GLP-1 (Victoza/Saxenda) para la diabetes tipo 2 y el control del peso.
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Curva teórica de concentración con una semivida de 13 h. Modelo farmacocinético puro — no es una recomendación de dosis.
Open in PK tool →Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial BMI ≥ 30 kg/m² or ≥ 27 kg/m² with weight-related comorbidities.
Saxenda may reduce the risk of major cardiovascular events including heart attack and stroke — the first GLP-1 analog for which the FDA confirmed this in an outcome trial.
Los péptidos vienen como polvo seco. Una vez disuelto en un líquido (reconstitución), esta calculadora responde a una única pregunta: ¿cuánta sustancia hay en un mililitro de solución después?
Solo ciencia, sin ventas. Cancela cuando quieras.
We store your email only for the newsletter. Unsubscribe anytime. Privacy